Cash Generation: Generated almost INR83 crores of cash during the quarter.
EBITDA Margin Expansion: Improvement of 300-350 basis points over the same quarter last year, attributed to:
Mix impact (200-250 bps)
Operating leverage (100 bps)
Seasonality (Q1 is a healthier quarter for core categories like face wash and sunscreen) (50 bps)
A non-recurring one-time opex benefit (specific amount not quantified)
Normalized EBITDA Margin: Approximately 12.5% after adjusting for the one-time benefit.
Working Capital: The company continues to be negative working capital.
Strategic and Operational Highlights
Growth Strategy: The company's growth is driven by a focused category strategy. Focus categories grew over 35% and now contribute 85% of the business.
Core Brand Performance: Mamaearth accelerated to high-teens growth, driven by hero SKUs:
Rice Face Wash is now the number one face wash.
Ubtan is growing in strong double digits.
Rosemary Shampoo is growing in strong double digits and has become an INR100 crore+ ARR ingredient.
Sun care grew very strongly.
Young Brands Performance: Portfolio (Aqualogica, Dr. Sheth's, BBlunt, Staze) grew over 40%.
The Derma Co. became the company's second brand to achieve an INR1,000 crore ARR and entered the 'teens EBITDA club'.
Its Face Cleansers category has a run rate of more than INR200 crores.
The Derma Co.'s offline contribution is ~20% (GT + MT), with a presence in close to 50,000 GT outlets.
Acquisition (BTM Ventures): Acquired in January, it reached an ARR of INR150 crores in the quarter, growing almost 100% since acquisition. Expanded into Maharashtra, new categories, and new channels.
Channel Performance:
E-commerce: 20%+ growth, driven by focus categories (>25% growth), gaining share in quick commerce, and Tier 2+ markets.
General Trade (GT): 40%+ secondary sales growth. Distribution inventory is under 30 days.
Modern Trade (MT): 40%+ offtake growth.
Market Share Gains: Gained 350 bps share in face washes and 160 bps in shampoos.
New Launch: Launched a new fragrance brand, FIKN, described as India's first elixir-based brand, clinically tested for 12-hour longevity. The launch design is patented by Honasa.
Guidance and Outlook
Long-Term Financial Targets: Reaffirmed commitment to a five-year plan aiming for a high-teens revenue CAGR and annual EBITDA margin expansion of 100-150 basis points to reach a 15% EBITDA margin.
FY27 Expectation: Management expects growth and margin expansion in FY27 to be better than the five-year CAGR average.
Mamaearth Growth: Expected to be a double-digit CAGR story over five years, with FY27 growth better than the average.
Gross Margin: Management expects calibrated price increases taken in late Q1 to offset inflationary pressures from packaging materials (linked to crude oil prices) in Q2. No impact on gross margin profile is anticipated.
Growth vs. Margin Priority: The stated five-year plan already assumes reinvestment into new brands and categories. Growth will be prioritized over margin, with the goal of delivering on the committed long-term targets.
Other Business Updates
Honasa Health: A subsidiary created to strategically pursue the nutrition and wellness category, seen as a "decadal opportunity."
Fluence Pharma Acquisition: The acquisition is still in the "condition precedent process." The company's strategy for Honasa Health includes both organic propositions and potential future inorganic opportunities to bolster capabilities.
Community Initiatives: Brands continued initiatives in tree planting, education, women's certifications in salons, providing fresh water, and health checkups.
